(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 May 2016 (19.05.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/075584 A1

(51) International Patent Classification:
*C12N 15/113* (2010.01) *A61K 31/7088* (2006.01)
*A61K 9/00* (2006.01) *A61P 31/14* (2006.01)
*A61K 47/26* (2006.01)

(21) International Application Number:
PCT/IB2015/058423

(22) International Filing Date:
30 October 2015 (30.10.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/077,647 10 November 2014 (10.11.2014) US
62/077,980 11 November 2014 (11.11.2014) US

(71) Applicant: **GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED** [GB/GB]; 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(72) Inventors: **HONG, Zhi**; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, Research Triangle Park, North Carolina 27709 (US). **LEIVERS, Martin R.**; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, Research Triangle Park, North Carolina 27709 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17**:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*


**Published**:

— *with international search report (Art. 21(3))*

(54) **Title**: COMBINATION LONG ACTING COMPOSITIONS AND METHODS FOR HEPATITIS C

FIGURE 1

Mean Rat Pharmacokinetics of Two Formulations of LAP HCV active agent Dosed Intramuscular (IM) and Subcutenaous (SC)




(57) **Abstract**: The present Invention relates to pharmaceutical compositions useful in the treatment or prevention or cure of viral infections, such as HCV infections, and diseases associated with such infections.

WO 2016/075584 A1